NLRP3 and asthma: The use of the NLRP3 inhibitor MCC950, the caspase-1 inhibitor Ac-YVAD-CHO and IL-1β neutralizing antibodies effectively reduce the asthma-induced inflammatory response [27], indicating that activation of the NLRP3 inflammasome and induction of IL-1β are important components in inflammation in the body.